Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Champions Oncology, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 23 | 25 | +2 |
| Shares | 5.61M | 5.63M | +21.3K (+0.4%) |
| Value | $31.5M | $27.6M | −$3.88M (−12.3%) |
New holders (5)
Institutions that held Champions Oncology, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Goldman Sachs Group Inc | 69,301 | $339.6K | 0.00% |
| Mesirow Financial Investment Management, Inc. | 12,380 | $60.7K | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 12,252 | $60.0K | 0.00% |
| Stifel Financial Corp | 11,192 | $54.8K | 0.00% |
| Simplex Trading, LLC | 1,597 | $7.00K | 0.00% |
Sold out (3)
Institutions that held Champions Oncology, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Ameriprise Financial Inc | 75,044 | $406.4K |
| Dimensional Fund Advisors LP | 26,839 | $145.2K |
| Aristides Capital LLC | 11,822 | $66.4K |